
07/23/2025
🧠Melatonin & Lymphatic Clearance of Brain Amyloid Substance ðŸ§
Alzheimer’s disease is characterized by brain deposits of amyloid β protein (Aβ), in tissue plaques and intracranial blood vessels. This may trigger a downstream cascade of oxidative and pro-inflammatory events which may contribute to the widespread death of neurons and dementia.
There are data connecting brain Aβ accumulation with the peripheral lymphatic system in mouse with amyloidosis.
Melatonin inhibit Aβ aggregation in the brain. An older study evaluated lymphatic Aβ clearance by treating a mouse model of AD amyloidosis with melatonin. A 2018 study confirmed that clearance of Aβ peptides is significant through the lymphatic and treatment with melatonin created important changes:
1- A statistically significant decreases in Aβ proteins in the brain.
2-A statistically significant increase in Aβ proteins in cervical and axillary lymph nodes of treated mice.
Thee researchers concluded that abnormalities in Aβ clearance through the lymphatic system may contribute to the development of cerebral amyloidosis. Melatonin may delay the onset of cognitive impairment in high risk populations.
📰 Pappolla MA, Matsubara E, Vidal R, et al. Melatonin Treatment Enhances Aβ Lymphatic Clearance in a Transgenic Mouse Model of Amyloidosis. Curr Alzheimer Res. 2018;15(7):637-642.